Realise the true power of your online, atline and offline biologics data
22 April 2021 | By IDBS
Register today for our on-demand upcoming webinar and discover more on about Polar High-Throughput Process Development (HTPD).
List view / Grid view
22 April 2021 | By IDBS
Register today for our on-demand upcoming webinar and discover more on about Polar High-Throughput Process Development (HTPD).
An algorithm which continuously processes new data has been developed to allow researchers to access and analyse single-cell sequencing information.
31 March 2021 | By
The new AdvanceBio Sialic Acid profiling and quantitation kit from Agilent provides workflows for the robust and rapid preparation of samples for sialic acid analysis, generating reliable downstream LC-FLD and LC-MS data.
In February 2021, US biotech company GenScript launched an updated version of its semi-automated system, AmMag™ SA Plus.
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.
Researchers have discovered that all childhood neuroblastomas come from sympathoblasts, making them a drug target to treat the condition.
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
A new study suggests bile acids may act as a valuable biomarker for diagnosing and tracking the progression of Parkinson's disease.
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
Disrupting the interaction between the MYC oncogene and its co-factor, host cell factor (HCF)–1, was sufficient to cause Burkitt’s lymphoma cells to self-destruct in vivo.
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
A single change to the structure of bacterial ribosomes prevents macrolide antibiotics from binding and killing the bacteria, according to a study.
According to a Public Health England study, prior SARS-CoV-2 infection provides 83 percent protection against reinfection but may not stop individuals spreading COVID-19.